

ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated
GOODSENSE

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

GDS-1128B-2022-1208

Drug Facts

Active ingredients (in each caplet)	Purpose
Acetaminophen 325 mg	Pain reliever
Chlorpheniramine maleate 2 mg	Antihistamine
Phenylephrine HCl 5 mg	Nasal decongestant

Uses

- temporarily relieves these symptoms of hay fever or other upper respiratory allergies:
 - headache
 - nasal congestion
 - sinus congestion and pressure
 - minor aches and pains
 - runny nose and sneezing
- helps clear nasal passages
- helps decongest sinus openings and passages
- temporarily relieves these additional symptoms of hay fever:
 - itching of the nose or throat
 - itchy, watery eyes

Warnings

Liver warning

This product contains acetaminophen. The maximum daily dose of this product is 10 caplets (3,250 mg acetaminophen) in 24 hours. Severe liver damage may occur if you take

- more than 4,000 mg of acetaminophen in 24 hours
- with other drugs containing acetaminophen
- 3 or more alcoholic drinks every day while using this product

Allergy alert

Acetaminophen may cause severe skin reactions. Symptoms may include:

- skin reddening
- blisters
- rash

If a skin reaction occurs, stop use and seek medical help right away.

Do not use

- with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist.
- if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
- if you have ever had an allergic reaction to this product or any of its ingredients

Ask a doctor before use if you have

- liver disease
- heart disease
- high blood pressure
- thyroid disease
- diabetes
- trouble urinating due to an enlarged prostate gland
- a breathing problem such as emphysema or chronic bronchitis
- glaucoma

Ask a doctor or pharmacist before use if you are

- taking sedatives or tranquilizers
- taking the blood thinning drug warfarin

When using this product

- **do not exceed recommended dosage**
- excitability may occur, especially in children
- drowsiness may occur
- alcohol, sedatives, and tranquilizers may increase drowsiness
- avoid alcoholic drinks
- be careful when driving a motor vehicle or operating machinery

Stop use and ask a doctor if

- nervousness, dizziness, or sleeplessness occur
- pain or nasal congestion gets worse or lasts more than 7 days
- fever gets worse or lasts more than 3 days
- redness or swelling is present
- new symptoms occur

These could be signs of a serious condition.

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children.

Overdose warning

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222). Quick medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.

Directions

- do not take more than directed (see overdose warning)

adults and children 12 years and over	- take 2 caplets every 4 hours - swallow whole; do not crush, chew, or dissolve - do not take more than 10 caplets in 24 hours
children under 12 years	ask a doctor

Other information

- store between 20°-25°C (68°-77°F) in a dry place
- retain carton for complete product information and warnings

Inactive ingredients

acesulfame potassium, colloidal silicon dioxide, croscarmellose sodium, flavor, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, pregelatinized starch, propylene glycol, stearic acid, talc, titanium dioxide

Questions or comments?

1-844-705-4384

PRINCIPAL DISPLAY PANEL

GOODSENSE®

NDC 50804-128-02

For Adults

Allergy Multi-Symptom

Acetaminophen, Chlorpheniramine Maleate, Phenylephrine HCl

Pain Reliever, Antihistamine, Nasal Decongestant

- Headache

- Sinus Pressure
- Nasal Congestion
- Runny Nose/Sneezing
- Itchy, Watery Eyes

Cool Taste

Instant Cooling Sensation

24 CAPLETS

May Cause Drowsiness

Actual Size



ALLERGY MULTI SYMPTOM

acetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated

Product Information			
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:50804-128
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ACETAMINOPHEN (UNII: 362O9ITL9D) (ACETAMINOPHEN - UNII:362O9ITL9D)	ACETAMINOPHEN	325 mg
CHLORPHENIRAMINE MALEATE (UNII: V1Q0O9OJ9Z) (CHLORPHENIRAMINE - UNII:3U6IO1965U)	CHLORPHENIRAMINE MALEATE	2 mg
PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII:1WS297W6MV)	PHENYLEPHRINE HYDROCHLORIDE	5 mg

Inactive Ingredients

Ingredient Name	Strength
ACESULFAME POTASSIUM (UNII: 23OV73Q5G9)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
FERRIC OXIDE YELLOW (UNII: EX438O2MRT)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)	
POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)	
STARCH, CORN (UNII: O8232NY3SJ)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
TALC (UNII: 7SEV7J4R1U)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	

Product Characteristics

Color	white (Off-White)	Score	no score
Shape	OVAL	Size	17mm
Flavor	MINT	Imprint Code	AAA;1128
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:50804-128-02	2 in 1 CARTON	08/01/2020	
1		12 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part341	08/01/2020	

